Delving into the Latest Updates on Apixaban with Synapse

The aim of this trial is to find out if a tablet called apixaban can reduce blood clots in people with lung cancer having chemotherapy or similar treatments. Apixaban is a type of oral anticoagulant ("blood thinner") that makes the blood less sticky to prevent blood clots forming.
The trial is trying to find out if apixaban it can reduce blood clots in people with lung cancer.
Participants will receive the following treatment:
• Apixaban or placebo, 2.5mg taken by mouth twice a day for 6 months. This treatment will be taken in addition to any treatment that they are receiving to treat their lung cancer.
Participants will need to:
* Sign a consent form to enter the trial.
* Take the trial treatment as directed by the research team
* Complete a participant diary to record when they took the trial treatment
* Complete the Quality of Life and Health resource use questionnaires.
* Female participants of childbearing potential must use adequate contraception during the trial and for at least 2 days after trial treatment has finished.

Start Date02 Mar 2026

Sponsor / Collaborator

University of Birmingham

NCT07237308

/ Not yet recruitingPhase 4IIT

A Multicenter Prospective Randomized Study to Evaluate the Efficacy of Apixaban and Clopidogrel on the Prevention of Recurrent Ischemic Stroke in Patients With Atrial Fibrillation and Cerebral Atherosclerosis

This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis. Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of symptomatic or asymptomatic recurrent ischemic lesions detected on brain MRI (DWI/FLAIR) at 30 ± 5 days after initiation of study medication.

Start Date01 Dec 2025

Sponsor / Collaborator

Yonsei University

100 Clinical Results associated with Apixaban

Login to view more data

100 Translational Medicine associated with Apixaban

Login to view more data

100 Patents (Medical) associated with Apixaban

Login to view more data

6,568

Literatures (Medical) associated with Apixaban

01 Feb 2026·BIOMATERIALS

Self-adaptive covalent coating for vascular stents: Coordinated coagulation-inflammation regulation to support re-endothelialization for atherosclerosis control

Article

Author: Xiao, Yun ; Zhang, Wenbin ; Wang, Yanan ; Chen, Zhezhe ; Luo, Rifang ; Ma, Boxuan ; Zhu, Qiongjun ; Wang, Yao ; Fu, Guosheng ; Wang, Yunbing ; Wang, Xiaoyu

Therapeutic-coated vascular stents are one of the key directions in the clinical treatment of atherosclerosis. However, vascular injury and implant stimulation trigger a feedback loop between coagulation and inflammation, impairing endothelial cell (EC) function, which is critical for long-term success in atherosclerotic vessels. Here, we designed a self-adaptive covalent coating stent that integrates thrombin-responsive release of apixaban as a coagulation modulator and an antioxidant polyphenol as an anti-inflammatory. This pathologic microenvironment-responsive coating regulates coagulation-inflammation loop post-implantation. The nanogels within the coating dynamically response to thrombin, the upstream initiator of coagulation-inflammation, to release apixaban in high thrombotic risk conditions while retaining it in low-risk states. Epigallocatechin gallate (EGCG), functioning as a cross-linker and the ROS scavagener, detaches in response to oxidative stress. As such, the coating enables blockade of coagulation-inflammation loop, synergistically protects ECs from inflammatory damage, promotes endothelial regeneration, and inhibits endothelial-to-mesenchymal transition (EndMT), efficiently modulating the inflammatory microenvironment via localized and coordinated regulation of coagulation-inflammation loop. Furthermore, the implantation in an atherosclerotic rabbit model demonstrated that the coating inhibits plaque deterioration linked to inflammation and endothelial damage. This dual-responsive strategy offers a promising avenue for therapeutic stents by mitigating the coagulation-inflammation loop and supporting endothelial repair in atherosclerotic vessels.

01 Jan 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Harmonizing drug analysis and sustainability: Spectroscopic quantification of antiplatelet-anticoagulant regimens

Article

Author: Elama, Heba Samir ; El Abass, Samah Abo ; Altamimi, Abdulmalik S A ; Elmansi, Heba ; Abdallah, Nora A ; Alossaimi, Manal A

One of the most commonly prescribed medications are antithrombotic agents which consisting of antiplatelet and anticoagulant medications. Currently, millions of patients rely on them to avoid blood-clot-related issues across various cardiovascular diseases. The combined administration of apixaban, aspirin and clopidogrel is an example of this therapy which can be used for the risk reduction in cardiovascular death. The importance of such medications encourages us to investigate novel analytical assay methods for determination of such drugs in dosage forms as well as in human plasma. Spectroscopic technique was the best choice to design new analytical methods due to its applicability and simplicity. Three spectroscopic methods were introduced for concurrent determination of apixaban, aspirin and clopidogrel. The designed methods were; A direct measurement for determination of apixaban without interference from the other two drugs (method I), Ratio spectra (method II) and first derivative ratio spectra (method III). The first method enables us to determine apixaban through direct measurement of its absorption spectrum at 310 nm with no reading from aspirin or clopidogrel. Ratio spectra method (method II) was performed at ΔP = 223.6-245.2 nm for aspirin, ΔP = 293.2-307.0 nm for apixaban and ΔP = 251.0-260.0 nm for clopidogrel. The third first derivative ratio spectra method was based on measuring apixaban at 255 nm, aspirin at 242 nm and clopidogrel at 260 nm using the other two analytes as a double divisor. The linearity of the designed methods was 0.5-18 μg/mL for apixaban by the three methods while were 2.0-28 μg/mL for both aspirin and clopidogrel by method II & III. These developed approaches were effectively applied for estimation of the three studied drugs in their raw materials, synthetic mixtures and dosage forms simultaneously. The co-administration of these treatments enables us to extend the application for determination of them in spiked human plasma without complicated procedures. The applied methods were validated following the ICH Q2(R1) guidelines. The greenness of the designed methods was evaluated using six different tools including; Analytical Eco-scale, GAPI, AGREE metrics, NEMI, whiteness and blueness assessment.

01 Jan 2026·INTERNATIONAL JOURNAL OF CARDIOLOGY

Clinical impact of kidney function in patients with atrial fibrillation receiving oral anticoagulants

Article

Author: Nagashima, Kouichi ; Sakamoto, Daisuke ; Okumura, Yasuo ; Watanabe, Ryuta ; Sotomi, Yohei ; Matsuoka, Yuki ; Sunaga, Akihiro ; Higuchi, Yoshiharu ; Nakatani, Daisaku ; Kanda, Takashi ; Kitamura, Tetsuhisa ; Okada, Katsuki ; Minamiguchi, Hitoshi ; Sakata, Yasushi

BACKGROUND:

Renal function influences the pharmacokinetics of oral anticoagulants in atrial fibrillation (AF), potentially affecting both efficacy and bleeding risk. However, its differential impact across specific agents remains unclear. In this study, we aimed to evaluate the association between renal function and ischemic and bleeding risks in patients with AF, with analyses stratified by anticoagulant type.

METHODS:

We analyzed 7239 patients with non-valvular AF from the DIRECT-Extend registry, a pooled dataset of three large-scale registries. Creatinine clearance (CrCl) was calculated using the Cockcroft-Gault formula and categorized into ≥50, 30 to <50, and 15 to <30 mL/min. The primary ischemic endpoint was stroke or systemic embolism, and the primary bleeding endpoint was major bleeding. Cox proportional hazard models and restricted cubic spline analyses assessed associations between CrCl and outcomes, with subgroup analyses by anticoagulant type.

RESULTS:

Lower CrCl was associated with older age, female sex, and greater comorbidity burden. Impaired renal function was significantly associated with higher ischemic and bleeding risks. Spline analysis demonstrated a continuous increase in both risks with declining CrCl, with a nonlinear relationship for bleeding. Subgroup analyses revealed significant associations between reduced CrCl and ischemic risk in patients on dabigatran, rivaroxaban, edoxaban, and warfarin. Increased bleeding risk was evident for edoxaban and warfarin at lower CrCl levels. No significant association was observed between CrCl and either endpoint in patients receiving apixaban.

CONCLUSION:

In this large real-world cohort, declining renal function was associated with increased ischemic and bleeding risks, highlighting the importance of renal function-based risk assessment in the management of anticoagulation therapy.

308

News (Medical) associated with Apixaban

26 Nov 2025

·www.pharmaceutical-technology.com

Questions on how new IRA drug prices will affect MFN agreements

The 15 drugs accounted for $42.5bn, translating to approximately 15% of total Medicare Part D spending in 2024. Credit: xsprtd via Shutterstock.com. As the US Centers for Medicare and Medicaid Services (CMS) has released the new prices for 15 drugs that have been added to the Inflation Reduction Act (IRA) an expert questions how closely these impact the Trump administration’s Most Favored Nation (MFN) policy. With the second round of IRA negotiations having been conducted under the Trump administration, GlobalData life sciences research analyst Cyrus Fan, questions what these two different price points will mean. Fan commented: “The negotiated prices and process give insight into how future rounds will be conducted. While the Trump administration has been advocating for lower drug prices, it has been promoting the MFN executive order more than the IRA. It is not clear how the negotiated prices under the MFN and the IRA will affect each other.” While agreements made under the IRA remain separate to those agreed under MFN and through direct to consumer (DTC) programmes, some agreements that pharma has made with the administration include deals to drop prices on Medicare and Medicaid. This includes Novo Nordisk, which reached a deal with the White House to cut Medicare prices for Wegovy and Ozempic to $245 a month under MFN; however, this drug is also included in IRA negotiations. Under the IRA, Novo Nordisk’s Wegovy and Ozempic have been reduced from a list price of $959 down to $274 for a 30-day supply – a higher price than agreed under MFN. Also on the list is Pfizer’s breast cancer drug Ibrance (palbociclib), which will go down to a cost of $7,871 from $15,741, reflecting a discount of 50%. Pfizer is another company that has come to an MFN agreement with the White House, but it does not appear that Ibrance is included in this agreement. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Drugs treating various cancers, asthma, and other chronic illnesses make up the remaining 13 drugs. The 15 drugs accounted for $42.5bn, translating to about 15% of total Medicare Part D spending in 2024. Medicare Part D covers outpatient prescription drugs. Overall, Medicare covers more than 67 million people aged 65 and over and those with disabilities. The lower prices for the tranche of drugs come via the Medicare Drug Price Negotiation Programme, under which CMS directly negotiates the prices of certain high-expenditure drugs with no biosimilar or generic competition. This is the second round of negotiations under the IRA programme, which was signed into law by former President Joe Biden in 2022. In August 2024, the Biden administration reached deals on ten prescription drugs , with the price cuts coming into effect in 2026. Medicines such as Pfizer and Bristol Myers Squibb’s blood thinner Eliquis (apixaban) and Amgen’s arthritis drug Enbrel (etanercept) were amongst the first batch negotiated. CMS said the Maximum Fair Prices (MFPs) for the 15 drugs will become effective on 1 January 2027, bringing the total number of negotiated drugs to 25. However, CMS administrator Mehmet Oz was keen to highlight the better discounts achieved this year compared to 2024. The Biden administration said the prices agreed last year are expected to save taxpayers $6bn and provide $1.5bn in savings for patients in 2026. “This year’s results stand in stark contrast to last year’s. Using the same process with a bolder direction, we have achieved substantially better outcomes for taxpayers and seniors in the Medicare Part D programme — not the modest or even counterproductive ‘deals’ we saw before,” Oz said. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

24 Nov 2025

·www.biospace.com

Bayer Sets Up Redemption Arc for Anticoagulant With ‘Surprisingly Positive’ Phase III Data

iStock, Tatyana Kim Asundexian’s Phase III win could also bode well for Bristol Myers Squibb, which is also developing a Factor XIa inhibitor called milvexian for stroke prevention, analysts said. Bayer’s investigational Factor XIa inhibitor asundexian significantly protected patients against stroke in the Phase III OCEANIC-STROKE study, setting the drug up for a comeback after a previous late-stage stumble. Without providing specific data, Bayer reported in a press announcement on Sunday that daily treatment with asundexian “significantly reduced the risk of ischemic stroke” versus placebo. OCEANIC-STROKE enrolled more than 12,300 patients who had suffered a non-cardioembolic ischemic stroke or high-risk ischemic attack. Participants were on antiplatelet therapy. Aside from hitting the primary endpoint, Bayer’s topline readout also showed that there was no increase in major bleeding risk for patients treated with asundexian. Asundexian’s stroke outcomes are “surprisingly positive,” Leerink Partners told investors in a note on Sunday evening. The OCEANIC-STROKE results come almost three years to the day after Bayer ended the Phase III OCEANIC-AF study of asundexian in atrial fibrillation, driven by what the pharma at the time called the drug’s “inferior efficacy” versus the blockbuster blood thinner Eliquis. Bayer did not provide specific data on the difference between asundexian and Eliquis at that time. According to a Sunday news release, Bayer will present OCEANIC-STROKE data to regulatory authorities worldwide, with an eye toward marketing authorization applications, though it did not provide a specific timeline. The pharma also promised to present the study’s full findings at an upcoming medical meeting. The OCEANIC-STROKE readout could have a “bullish readthrough” to another investigational FXIa inhibitor, milvexian, being tested by Bristol Myers Squibb and Johnson & Johnson for secondary stroke prevention. A Phase III readout for the drug is expected in the fourth quarter of next year. BMO Capital Markets sees a similar upside to BMS and J&J’s candidate: Bayer’s asundexian “acts as an oral Factor XIa inhibitor, similar to Bristol’s milvexian,” the analysts explained, “mildly improving our confidence in Bristol’s overall approach to improve anticoagulant therapies without increasing bleeding risk.” Like asundexian, milvexian has a checkered development history. An interim analysis earlier this month showed that it was unlikely to meet the primary endpoint in a late-stage study of acute coronary syndrome. The companies ultimately discontinued the trial. Still, BMO analysts remain cautiously optimistic, noting that they still need to see the full data from OCEANIC-STROKE to better “assess the clinical relevance of benefits” of Factor XIa inhibition on stroke risk.

Phase 3

23 Nov 2025

·firstwordpharma.com

Bayer claims late-stage win for asundexian in secondary stroke prevention

After disappointing last year in atrial fibrillation (AF), Bayer's oral factor XIa inhibitor has now notched a win in secondary stroke prevention. The German drugmaker said Sunday it's prepping global regulatory applications after asundexian met its primary efficacy and safety endpoints in the Phase III OCEANIC-STROKE study. The trial enrolled over 12,300 participants who had experienced a non-cardioembolic ischemic stroke or high-risk ischemic attack to receive 50-mg asundexian daily or placebo, both in combination with antiplatelet therapy. Bayer's factor XIa inhibitor significantly reduced the risk of ischemic stroke compared to placebo, without increasing the risk of major bleeding. The company plans to present detailed data from OCEANIC-STROKE at an upcoming scientific meeting."Even with currently available therapies, the risk of another stroke remains high, and each recurrence can have profound consequences," said Mike Sharma, the study's principal investigator. "The topline results from OCEANIC-STROKE indicate that asundexian may become a new treatment option to reduce this risk — representing a potential major step forward in secondary stroke prevention."While the findings from OCEANIC-STROKE are positive, secondary stroke prevention is a smaller market opportunity than primary prevention — though Bayer's hopes for a regulatory win in the larger indication are likely dashed (see – ViewPoints: How Bayer’s BD team is building out its cardiovascular pipeline).Last year, Bayer reported that asundexian did not match Eliquis (apixaban) in preventing strokes and systemic embolism in patients with AF in the Phase III OCEANIC-AF study. Analysts had suggested the AF indication represented around €4 billion ($4.4 billion) of the €5.5 billion ($6.1 billion) peak sales estimate for the drug (see – KOL Views Q&A: Anthos, BMS hoping potency will separate factor XI wheat from chaff in wake of asundexian setback).

Phase 3Clinical Result

100 Deals associated with Apixaban

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03213	Apixaban	B01AF02	DB06605

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Recurrent deep vein thrombosis	European Union	Accord Healthcare SLU	23 Jul 2020
Recurrent deep vein thrombosis	Iceland	Accord Healthcare SLU	23 Jul 2020
Recurrent deep vein thrombosis	Liechtenstein	Accord Healthcare SLU	23 Jul 2020
Recurrent deep vein thrombosis	Norway	Accord Healthcare SLU	23 Jul 2020
Thrombosis	China	Bristol-Myers Squibb/Pfizer EEIG	22 Jan 2013
Ischemic stroke	Japan	Bristol-Myers Squibb KK	25 Dec 2012
Systemic embolism	Australia	Bristol Myers Squibb Co.	21 Jul 2011
Atrial Fibrillation	European Union	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Atrial Fibrillation	Iceland	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Atrial Fibrillation	Liechtenstein	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Atrial Fibrillation	Norway	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Embolism	European Union	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Embolism	Iceland	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Embolism	Liechtenstein	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Embolism	Norway	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Pulmonary Embolism	European Union	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Pulmonary Embolism	Iceland	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Pulmonary Embolism	Liechtenstein	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Pulmonary Embolism	Norway	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Stroke	European Union	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Limb-Threatening Ischemia	Phase 3	Brazil	Wyeth AB	09 Jan 2020
Cognitive Dysfunction	Phase 3	United States	Bristol Myers Squibb Co.	19 Dec 2018
Cognitive Dysfunction	Phase 3	United States	Pfizer Inc.	19 Dec 2018
Basal Cell Carcinoma	Phase 3	Austria	Bristol Myers Squibb Co.	11 Oct 2018
Basal Cell Carcinoma	Phase 3	Belgium	Bristol Myers Squibb Co.	11 Oct 2018
Basal Cell Carcinoma	Phase 3	Canada	Bristol Myers Squibb Co.	11 Oct 2018
Basal Cell Carcinoma	Phase 3	France	Bristol Myers Squibb Co.	11 Oct 2018
Basal Cell Carcinoma	Phase 3	Greece	Bristol Myers Squibb Co.	11 Oct 2018
Basal Cell Carcinoma	Phase 3	Italy	Bristol Myers Squibb Co.	11 Oct 2018
Basal Cell Carcinoma	Phase 3	Netherlands	Bristol Myers Squibb Co.	11 Oct 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01938248 (ARTESiA, Pubmed \| JAMA Cardiol)	Phase 4	Atrial Fibrillation	3,961	Apixaban 5 mg, twice daily (2.5 mg twice daily when indicated)	pyvblvtxzs(lqzaojasbn) = pcuxowjmiu unofjffcky (dkckmbzwyf ) View more	Positive	12 Nov 2025
				Aspirin 81 mg, once daily	pyvblvtxzs(lqzaojasbn) = cmgufhpjnd unofjffcky (dkckmbzwyf ) View more
NCT04168203 (HI-PRO, CTgov)	Phase 4	Pulmonary Embolism \| Venous Thrombosis \| Venous Thromboembolism	600	Apixaban 2.5 MG (Extended Duration Thromboprophylaxis)	hvfhmgrgww = awhffweaek hlkpmirrps (gewxmndwbh, xwjogtipuf - yawakblllo) View more	-	30 Sep 2025
				Placebo oral tablet (Control)	hvfhmgrgww = iytkiewyfd hlkpmirrps (gewxmndwbh, gpefgfbqmu - lgsgxiuwgm) View more
NCT03192215 (ARCADIA-Cognition, Pubmed \| J Am Heart Assoc)	Phase 3	Cryptogenic Ischemic Stroke \| Heart Diseases atrial cardiopathy	249	Apixaban	opfffyraag(xifkndhcux) = pyqmgauenp pavwuvldhz (ttefxzwjzo, 0.041 - 0.174)	Negative	16 Sep 2025
				Aspirin	opfffyraag(xifkndhcux) = fjqbyiecdk pavwuvldhz (ttefxzwjzo, 0.017 - 0.149)
NCT05438888 (Pubmed \| Cardiol Ther)	Not Applicable	Atrial Fibrillation	-	Apixaban	fbgruokprt(psypapslrr) = kvaixhawhz tgyrqgbvkv (ehirwbvtfs ) View more	Positive	08 Jul 2025
				Warfarin	fbgruokprt(psypapslrr) = utkzrefwaz tgyrqgbvkv (ehirwbvtfs ) View more
NCT04504318 (CTgov)	Phase 1/2	Venous Thromboembolism	82	Apixaban 2.5 MG Oral Tablet (Apixaban)	bjwouqjlpk = qzuqvbfycl tvojpaqool (wlylrspmur, qxihkokxsk - frhrwwsbod) View more	-	22 Jun 2025
				Enoxaparin (Enoxaparin)	bjwouqjlpk = zcnszvesmx tvojpaqool (wlylrspmur, zxknumejzq - hzrcgmnccv) View more
NCT03045406 (CARAVAGGIO, CTgov)	Phase 3	Basal Cell Carcinoma \| Neoplasms \| acute leukemia ... View more	1,170	Apixaban (Apixaban)	dshunxmmdg = eylebwxecr lcpfauhblz (gjhdmlfgee, gttjdjtmax - olhcdljkhr) View more	-	18 Jun 2025
				Dalteparin (Dalteparin)	dshunxmmdg = zjjrykhzty lcpfauhblz (gjhdmlfgee, hhgeqtnfxy - wydodacflb) View more
NCT05643573 (OCEANIC-AF, Pubmed \| JAMA Cardiol)	Phase 3	Atrial Fibrillation	-	Asundexian	cfqoomzjem(rwnsperenu) = wrzjefyfxu mxqdjvpqyv (htdkstqmyw )	Positive	01 Jun 2025
				Apixaban	cfqoomzjem(rwnsperenu) = kmwdjmfcro mxqdjvpqyv (htdkstqmyw )
PB3023 (EHA2025)	Not Applicable	Multiple Myeloma	101	NOACs (Apixaban 2.5 mg twice daily, Rivaroxaban 10-20 mg per day)	ttsygchwze(xkgzwxtufn) = Thromboembolic events were observed in only two patients as acute DVTs wvxwwcjpsv (wejpuckycq ) View more	Positive	14 May 2025
NCT03192215 (ARCADIA, Pubmed \| J Cardiovasc Electrophysiol)	Phase 3	Atrial Premature Complexes \| Heart Diseases NT‐proBNP \| P‐wave terminal force \| left atrial diameter index ... View more	1,015	Apixaban	bmxdjqiidu(mebtulpbro) = kgbezdbdjk cfxvcttwdx (qlqhacjocg )	Negative	28 Apr 2025
				Aspirin	bmxdjqiidu(mebtulpbro) = kkvcfopedw cfxvcttwdx (qlqhacjocg )
NCT03692065 (API-CAT, Pubmed \| N Engl J Med)	Phase 3	Venous Thromboembolism	1,766	Apixaban 2.5 mg	kojffkwfzz(qundlhbadt) = ctzwypajnl eetvkzsnjl (lwldedshzl ) View more	Positive	10 Apr 2025
				Apixaban 5.0 mg	kojffkwfzz(qundlhbadt) = jojndabrad eetvkzsnjl (lwldedshzl ) View more